Results 71 to 80 of about 2,554,026 (187)

Critical appraisal of the role of pegloticase in the management of gout

Open Access Rheumatology: Research and Reviews, 2012
Hang-Korng Ea,1,2 Pascal Richette1,21Hôpital Lariboisière, Rheumatology Department, Paris, France; 2University of Paris Diderot, Sorbonne Paris Cité, Paris, FranceAbstract: Gout is a debilitating disease secondary to ...
Ea HK, Richette P
doaj  

Management of gout: Primary care approach

South African Family Practice, 2009
Great strides have been made in understanding gout as a disease over the centuries. Despite these advances, reports suggest that the management of gout is relatively sub-optimal at the primary care level.
Olufemi Omole, Gboyega A. Ogunbanjo
doaj   +1 more source

Effectiveness of Telehealth Low‐Carbohydrate Intervention in Preventing Chronic Kidney Disease: A Real‐World, Retrospective, Matched Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9054-9068, October 2026.
ABSTRACT Background Lifestyle interventions targeting metabolic health may influence chronic kidney disease (CKD) risk, particularly among adults with type 2 diabetes and obesity. We evaluated real‐world associations between a telehealth‐delivered, individualized nutrition therapy program (VINT) and CKD incidence and progression compared with usual ...
Shaminie J. Athinarayanan, Petter Bjornstad, Priya V. Shanmugam, Thomas Weimbs, Adam J. Wolfberg, Jeff S. Volek, Jonathan Himmelfarb, Richard J. Johnson   +7 more
wiley   +1 more source

Variations in the Management of Uncontrolled Gout Between Rheumatologists and Nephrologists: A Retrospective Medical Record Review

ACR Open Rheumatology, Volume 8, Issue 9, September 2026.
Objective To evaluate the management practices of rheumatologists and nephrologists in treating patients with uncontrolled gout. Methods US board‐certified rheumatologists and nephrologists treating patients with uncontrolled gout participated in a web‐based, retrospective medical record audit study, sharing their perceptions of uncontrolled gout ...
Kenneth Saag, Nana Kragh, Amod Athavale, Bhavisha Desai, Amal Gulaid, Abiola Oladapo, Brittany Smith, Hyon Choi   +7 more
wiley   +1 more source

Urate-lowering therapy in maintenance hemodialysis: focusing on gout burden rather than serum urate alone

Renal Replacement Therapy
Background Whether asymptomatic hyperuricemia should trigger pharmacologic intervention in maintenance hemodialysis remains unresolved. This question differs fundamentally from hyperuricemia management in the general population or in nondialysis chronic ...
Yoshitaka Furuto, Daiki Yoshino, Akio Namikawa, Dai Sato, Yuko Shibuya   +4 more
doaj   +1 more source

Longitudinal Serum Uric Acid Variation and Risk of Major Adverse Cardiovascular Events and Mortality: A Systematic Review and Meta‐Analysis

Clinical Cardiology, Volume 49, Issue 9, September 2026.
A systematic review and meta‐analysis of six cohort studies (160 640 participants) demonstrated that greater longitudinal serum uric acid variability was independently associated with increased risks of all‐cause mortality, cardiovascular disease, cardiovascular mortality, and heart failure‐related outcomes.
Saima Nisar, Asif Shah, Abida Perveen
wiley   +1 more source

Cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data [PDF]

BackgroundInitiating urate-lowering therapy can trigger gout flares. Gout flares have been associated with a temporally increased risk of cardiovascular events.
Avery, Anthony, Choi, Hyon, Abhishek, Abhishek, McCormick, Natalie, Yokose, Chio, Mamas, Mamas, Tata, Laila, Nakafero, Georgina, Cipolletta, Edoardo   +8 more
core   +1 more source

When Joint Aspiration Fails: Point‐of‐Care Ultrasound for Diagnosing Chronic Gout in Prolonged Monoarthritis

Journal of General and Family Medicine, Volume 27, Issue 5, September 2026.
ABSTRACT Background A 34‐year‐old man presented to our primary care clinic with persistent pain and swelling of the right first metatarsophalangeal joint lasting 3 months. A previous clinic had suspected gout based on hyperuricemia, but urate‐lowering therapy was repeatedly withheld because of ongoing inflammation, resulting in prolonged symptoms ...
Takayuki Yamada
wiley   +1 more source

Intelligent design of artificial biocatalyst for biomedical diseases

Journal of Intelligent Medicine, Volume 3, Issue 3, Page 220-249, September 2026.
This review summarizes recent advances in the intelligent design of artificial biocatalysts for biomedical diseases. By leveraging tailored design strategies, including environment‐responsive engineering and rational/artificial intelligence‐aided optimization, these biocatalysts enable precise modulation of pathological microenvironments and targeted ...
Lijie Zhang, Nan Song, Huanhuan Qiao, Si Sun   +3 more
wiley   +1 more source

Association of Sodium‐Glucose Cotransporter‐2 Inhibitors With Incident Gout Risk: A Population‐Based Comparative Cohort Study With Genetic Evidence From Mendelian Randomisation

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8230-8241, September 2026.
ABSTRACT Aim Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are known to reduce serum urate levels, yet their specific impact on gout incidence in the Korean population remains underexplored. We investigated the association between SGLT2i use and incident gout using real‐world data and Mendelian randomisation (MR) analysis. Materials and Methods We
Hong Sang Choi, Jaejun Heo, Sungho Won, Sang Heon Suh, Chang Seong Kim, Eun Hui Bae, Juhee Ahn, Soo Wan Kim   +7 more
wiley   +1 more source